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Statement of Translational relevance:  
Many prostate cancers diagnosed today are likely indolent, but better means of 
assessing prostate cancer prognosis are needed to identify the appropriate, patient-
specific treatment option. Distinguishing tumors of Gleason score 6 from tumors of 
Gleason score ≥7 is especially critical for assessing eligibility for active surveillance 
(AS). In patients who underwent diffusion-weighed MRI before radical prostatectomy, 
we assessed the value of the mean tumor apparent diffusion coefficient (ADCmean) and 
the tumor volume measured from ADC maps (VolumeADC) for predicting two important 
prognostic factors: tumor volume and tumor Gleason score on histopathology. 
VolumeADC correlated well with histopathologic tumor volume, and the strength of the 
correlation increased with the tumor Gleason score. Both VolumeADC and ADCmean 
correlated with tumor Gleason score, but on multivariate analysis only ADCmean 
independently distinguished tumors of Gleason Score 6 from tumors of Gleason Score 
≥7. Our findings indicate that independent of the tumor volume, ADCmean could serve as 
a biomarker to predict prostate cancer aggressiveness.  
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Abstract 
Purpose 
To investigate whether tumor volume derived from apparent diffusion coefficient (ADC) 
maps (VolumeADC) and tumor mean ADC value (ADCmean) are independent predictors of 
prostate tumor Gleason score (GS). 
Materials and Methods 
Tumor volume and GS were recorded from whole-mount histopathology for 131 men 
(median age, 60) who underwent endorectal diffusion-weighted magnetic resonance 
imaging for local staging of prostate cancer before prostatectomy. VolumeADC and 
ADCmean were derived from ADC maps and correlated with histopathologic tumor 
volume and GS. Uni- and multivariate analyses were performed to evaluate prediction 
of tumor aggressiveness. Areas under receiver-operating-characteristics curves (AUCs) 
were calculated to evaluate the performance of VolumeADC and ADCmean in 
discriminating tumors of GS 6 and GS ≥7. 
Results 
Histopathology identified 116 tumor foci >0.5 mL. VolumeADC correlated significantly 
with histopathologic tumor volume (ρ=0.683). The correlation increased with increasing 
GS (ρ=0.453 for GS 6 tumors; ρ=0.643 for GS 7 tumors; ρ=0.980 for GS≥8 tumors). 
Both VolumeADC (ρ=0.286) and ADCmean (ρ=-0.309) correlated with GS. At univariate 
analysis, both VolumeADC (p=0.0325) and ADCmean (p=0.0033) could differentiate GS=6 
from GS≥7 tumor foci. However, at multivariate analysis, only ADCmean (p=0.0156) was 
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a significant predictor of tumor aggressiveness (i.e., GS 6 vs. GS ≥7). For differentiating 
GS 6 from GS≤7 tumors, AUCs were 0.644 and 0.704 for VolumeADC and ADCmean, 
respectively, and 0.749 for both parameters combined. 
Conclusion 
In patients with prostate cancer, ADCmean is an independent predictor of tumor 
aggressiveness, but VolumeADC is not. The latter parameter adds little to the ADCmean in 
predicting tumor Gleason score.  
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Introduction 
It was estimated that 30% to 50% of the approximately 238,590 American men 
diagnosed with prostate cancer (PCa) in 2013 would have an indolent form of the 
disease unlikely to become life-threatening. These men could potentially take 
advantage of an increasing spectrum of patient-tailored disease management options—
including active surveillance and various forms of focal ablation—that are designed to 
minimize adverse treatment-related effects (1-3). However, to ensure that patients are 
indeed suited for such conservative management approaches, it is essential not only to 
detect and localize PCa, but also to assess its aggressive potential—a task that remains 
challenging. Clinical, biochemical and pathological features are typically used to triage 
patients according to the likelihood of rapid disease progression (4-8).  
Recently, diffusion-weighted magnetic resonance imaging (DWI) has garnered 
interest for its potential to non-invasively characterize PCa aggressiveness. DWI probes 
variations in free water movement within tissues, which tends to be more restricted in 
the presence of tumor due to changes in cell number, size and architecture. On DWI 
images, variations in water diffusion manifest as changes in signal intensity, and 
degrees of diffusion restriction can be assessed quantitatively by means of the apparent 
diffusion coefficient (ADC). A relatively simple metric, the ADC can be calculated on a 
pixel-by-pixel basis with clinical MRI platforms. A number of studies have shown an 
inverse correlation between ADC values on DWI and prostate cancer Gleason scores 
(9-14). However, the ADC values of PCa foci with different Gleason scores overlap, and 
no method has been developed to determine the Gleason score unequivocally based on 
ADC analysis alone (9-14).  
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Pathology studies have shown that higher tumor volumes are associated with 
higher Gleason scores and worse outcomes (15, 16). Tumor volume measured on DWI 
correlates well with the histopathologic tumor volume (17, 18). However, the relationship 
between ADC and prostate tumor volume and the potential synergy of these two 
parameters in evaluating PCa aggressiveness have not been explicitly explored. Thus, 
the purpose of our study was to investigate whether tumor mean ADC value and tumor 
volume derived from ADC maps are independent predictors of tumor Gleason score and 
can be used to distinguish tumors with Gleason scores of 6 from those with Gleason 
scores of 7 or above. 
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Materials and Methods 
The institutional review board approved our retrospective study and waived the 
informed consent requirement. Our study was compliant with the Health Insurance 
Portability and Accountability Act. 
 
Patients 
Patients who underwent MRI of the prostate including DWI between July 2008 
and April 2010 and for whom whole-mount step-section pathologic tumor maps were 
available were identified (n=377). Patients who met the following inclusion criteria were 
selected: 1) 1.5-Tesla MRI of the prostate, including a DWI sequence with b=0, 1000 
s/mm2; 2) radical prostatectomy performed at our institution within 6 months after MRI. 
Patients were excluded if a) they had undergone prior prostate cancer treatment, 
including hormone therapy or radiation; b) acquisition was incomplete or imaging 
artifacts rendering the examination non-diagnostic were present; or c) MRI was 
performed without an endorectal coil. Our final study population consisted of 131 
consecutive patients who were previously included in a study analyzing histogram-
derived apparent diffusion coefficient (ADC) parameters (19). Patients’ characteristics 
are summarized in Supplemental Table 1.  
 
MRI Acquisition 
Research. 
on March 25, 2015. © 2014 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on May 21, 2014; DOI: 10.1158/1078-0432.CCR-14-0044 
All images were acquired on a 1.5-Tesla MRI system (GE Healthcare 
Technologies, Waukesha, WI). A body coil was used for excitation; a pelvic four-
channel phased-array coil and an endorectal coil (Medrad, Warrendale, Pa) were used 
for signal reception. T1-weighted, T2-weighted and DWI sequences were acquired but 
only DWI sequence was used for analysis in this study. DWI was performed using a 
single-shot spin-echo echo-planar imaging sequence with b=0, 1000 s/mm2 (TR/TE, 
1200-6800ms/40-113ms; section thickness, 3-4mm; no intersection gap; FOV, 12-16 
cm; matrix, 96 x 96 - 128 x 128). Parametric maps of ADC values were calculated using 
a designated workstation (Advanced Workstation, GE Medical Systems). 
 
MRI - Histopathologic Correlation 
Histopathologic Preparation 
After prostatectomy, specimens were submitted to histopathology, where they 
were sliced from apex to base at 3-4-mm intervals. Microslices were placed on glass 
slides and stained with hematoxylin-eosin after paraffin embedding. For each patient, 
one of two dedicated genitourinary pathologists at our institution with more than 30 
years of combined experience verified,and assigned a Gleason score for (GS) for each 
tumor outlined on the histology slides.  
Measurement of Histopathologic Tumor Volume 
Tumor volume on pathology slices was measured in consensus by two of the 
authors using software (ImageJ, version 1.47a; National Institutes of Health, Bethesda, 
Md). If a lesion extended into more than one pathologic slice, the areas of tumor foci on 
all slices were summed to obtain an estimate of the histopathologic volume of the whole 
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lesion. Tumors that covered both zones - the transition zone (TZ) as well as the 
peripheral zone (PZ) - were considered to be TZ tumors if more than 70% of the tumor 
was in the TZ (20); all others were considered to be PZ tumors (9). 
Correlation of Lesions on MRI and Histopathology  
Working in consensus, three radiologists (with 1, 1 and 9 years of experience in 
interpreting prostate MRI,) correlated MR images with whole-mount pathology maps to 
establish the locations of tumors on MRI. Using software (ImageJ, version 1.47a; 
National Institutes of Health, Bethesda, Md), the radiologists drew a freehand region of 
interest around the discernible tumor tissue on the ADC maps (19). If a tumor was 
depicted on more than one slice, all traced ROIs corresponding to that tumor were 
included in the estimation of the tumor volume (VolumeADC) and the calculation of the 
mean ADC value (ADCmean) (19). On each slice containing tumor, the area of the tumor 
focus was determined on a voxel-basis by considering the acquisition matrix, 
reconstruction matrix as well as the FOV. VolumeADC [mL] was calculated as (sum of all 
tumor areas on the slices (cm2) x slice thickness (cm)). 
 
 
Statistical Analysis 
The correlation between VolumeADC and volume derived from histopathology as 
well as the correlations of VolumeADC  and ADCmean with tumor GS were assessed using 
Spearman’s correlation coefficient (ρ). The between-subject correlation coefficient 
proposed by Bland and Altman (21) was calculated and tested to take into account 
multiple lesions per patient.   
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To evaluate whether VolumeADC and ADCmean could differentiate a GS of 6 from a 
GS ≥ 7, a generalized linear regression and generalized estimating equations method 
was used with an independent correlation structure and robust covariance matrix, to 
take into account multiple lesions per patient. Univariate and multivariate analyses with 
both VolumeADC and ADCmean as covariates were performed. The odds ratio (OR) 
describing the likelihood of a tumor having GS≥7, along with the 95% confidence 
interval (CI), was estimated. Nonparametric receiver operating characteristic (ROC) 
curve analysis was performed, and the area under the curve (AUC) was estimated to 
evaluate the performance of VolumeADC and ADCmean in discriminating between GS 6 
and GS≥7. Sensitivity and specificity based on the estimated probabilities from the 
multivariate model were used to estimate the AUC for the combination of both variables. 
All statistical analyses were performed with SAS 9.2 (SAS Institute Inc., Cary, 
NC, USA) and R version 2.13 (The R Foundation for Statistical Computing). Results 
with p-values < 0.05 were considered statistically significant. 
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Results 
Forty-six patients presenting only insignificant cancer lesions in terms of volume 
(≤0.5mL) (22) were excluded from comparative analysis. One hundred sixteen clinically 
significant lesions (>0.5mL) on histopathology were found in 85 patients. Eighty-nine 
(76.7%) of the 116 lesions originated in the PZ and 27/116 (23.3%) originated in the TZ. 
Lesion characteristics including tumor volume and GS are shown in Supplemental 
Table 2.  
 
Correlation of VolumeADC and Histopathologic Tumor Volume 
The Spearman’s correlation coefficient for VolumeADC and histopathologic tumor 
volume in lesions >0.5 mL was ρ=0.683 (p<0.0001) (Figure 1). The correlation 
coefficient increased as the tumor GS increased, rising from ρ=0.453 (p=0.1042) for 
tumors with a GS of 6 (3+3), to ρ=0.643 (p<0.0001) for tumors with a GS of 7 (3+4 or 
4+3) and ρ=0.980 (p<0.0001) for tumors with a GS ≥ 8 (Table 1). The correlation 
between histopathologic tumor volume and VolumeADC was highest for tumors of GS≥8.  
 
Correlations of Histopathologic Tumor Volume, VolumeADC and ADCmean with GS 
Histopathologic tumor volume and VolumeADC both correlated positively with 
tumor GS (ρ=0.336 [p=0.0017] and ρ=0.286 [p=0.0081], respectively), while ADCmean 
correlated negatively with tumor GS (ρ=-0.309 [p=0.0087]).  
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Differentiation of Tumor Aggressiveness by VolumeADC and ADCmean 
 In a univariate analysis including all lesions (PZ and TZ), both VolumeADC and 
ADCmean could differentiate tumors of GS 6 from those with a GS ≥ 7 (odds ratio, 1.73 
for VolumeADC and 0.64 for ADCmean; p-values, p=0.0325 and p=0.0033, respectively) 
(Table 2). In a sub-analysis considering only tumors originating in the PZ, 
ADCmean,could differentiate between tumors of GS 6 and those with a GS ≥ 7 
(p=0.0025), but VolumeADC could not (p=0.2709) (Table 2). The number of lesions 
originating in the TZ was too small to permit a sub-analysis.  
 In a multivariate analysis, after adjustments were made for the influence of 
VolumeADC, ADCmean independently discriminated between tumors of GS 6 and tumors 
with a GS ≥ 7 (p=0.0156) (Figure 2). However, after adjustments were made for the 
influence of ADCmean, VolumeADC could not independently differentiate between these 
two tumor Gleason score categories (p=0.0733) (Table 2, Figure 3).  
Accuracy in discriminating tumors of GS 6 from those with a GS ≥ 7 was slightly 
lower for VolumeADC than for ADCmean (AUC=0.644 and AUC=0.704, respectively; 
p=0.3262). Combining these variables as covariates in a multivariate model resulted in 
a minor increase in AUC (to 0.749) (Supplemental Figure 1). 
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Discussion 
 In our study, tumor volume measured on ADC maps correlated with tumor 
volume on histopathology, and the strength of the correlation increased with the tumor 
Gleason score. In addition, the tumor mean ADC value - but not the tumor volume 
derived from ADC maps - independently differentiated tumors of Gleason score 6 from 
those of Gleason score 7 or above. The tumor volume derived from ADC maps 
(VolumeADC) added little to the tumor mean ADC value (ADCmean) in predicting the tumor 
Gleason score.  
 The correlation between VolumeADC and histopathologic tumor volume in our 
study (Spearman’s correlation coefficient [ρ] = 0.68) was very similar to that reported by 
Isebaert et al. (ρ=0.75) (17), and it was slightly higher than the correlation between 
tumor volume on T2-weighted MRI and histopathologic tumor volume reported by 
Turkbey et al. (ρ=0.63) (23). The difference between our result and that of Turkbey et al. 
is consistent with an earlier study by Mazaheri et al., which found that prostate cancer 
tumor volume measurements based on ADC maps correlated better with 
histopathologic tumor volumes than did measurements based on T2-weighted MRI (17, 
18). Furthermore, the correlation between imaging- and histopathology-derived tumor 
volumes may have been stronger in our study because, unlike Turkbey et al., we used a 
pixel-based calculation to determine imaging and histopathologic tumor volumes, 
outlining tumor borders instead of using the ellipsoid formula, which is based on linear 
measurements and does not take into account the irregular shapes of PCa foci.  
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In keeping with the existing literature, we demonstrated that ADC-based tumor 
volume and histopathologic tumor volume correlate better in PCa foci with higher 
Gleason scores. This may be explained by the fact that tumors with higher Gleason 
scores are better depicted on ADC maps because they contrast more strongly with 
benign tissue (10, 13); this makes it easier to trace the borders of the lesions and likely 
results in more accurate representations of the actual areas of tumor on ADC maps.  
 The correlation between VolumeADC and GS in our study (ρ=0.29) was similar to 
that recently reported by Verma et al. (ρ=0.35) (24). Likewise the correlation between 
ADCmean and GS in our patient cohort (ρ=-0.31) was within the range of such 
correlations reported in recent studies (ρ=-0.26 to -0.38) (12, 14, 24). At multivariate 
analysis, ADCmean was the only parameter that independently predicted the category of 
the tumor GS (GS 6 vs. GS ≥ 7).  It appears that though the predictive value of ADCmean 
for tumor aggressiveness is independent of tumor size, when ADCmean is not clearly 
predictive, VolumeADC cannot be used to resolve the ambiguity. These results contrast 
with those of a recent study by Verma et al., in which both mean ADC value and 
VolumeADC  were identified as significant predictors of tumor aggressiveness in the PZ 
at multivariate analysis (24). There are several possible reasons for the discrepancy. 
First, different statistical methods were used for the multivariate analyses of the two 
studies. Second, our measurements were based on whole-mount step-section 
pathology slides instead of recreated histologic maps. Third, the b-values used to create 
the ADC maps in our patient cohort (b=0, 1000 s/mm2) differed from those used in the 
other study (b=0, 600 s/mm2) (24). (ADC values are dependent on the chosen b-values 
(25), and therefore ADC measurements cannot be compared between protocols using 
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different b-values. However, as long as the imaging parameters, including the b-value, 
are kept constant, ADC values measured in the abdomen may be comparable across 
different scanners and field strengths (26)). Fourth, in the study by Verma et al., only the 
voxels of the most central slice were used to calculate ADC parameters. Although the 
results of the multivariate analyses differed, accuracy levels in identifying PCa foci of 
GS ≥ 7 by combining ADCmean and VolumeADC were similar in the two studies (24).  
We acknowledge the following limitations of our study: First, so that we would be 
able to correlate imaging findings with histopathology, we only included patients who 
underwent radical prostatectomy, causing a selection bias. Therefore our results may 
not apply to a broader population of patients with newly diagnosed prostate cancer, 
especially since there is a trend for increasing use of active surveillance of low-risk 
prostate cancer (27). However, this selection bias is inherent to every study that uses 
whole-mount step-section histopathology specimens as a reference standard for 
evaluating imaging variables. Second, an endorectal coil was used for acquisition of 
MRI, potentially deforming the prostate gland and the tumor foci. However, the use of 
an endorectal coil provides a higher signal-to-noise ratio (28) and may therefore be 
preferable for quantitative ADC analysis. Third, our approach of retrospectively 
delineating the prostate cancer foci on ADC maps using the histopathology maps as a 
guide does not represent the sequence of events in the clinical setting, where 
histopathology maps would not be available at the time of MRI. Therefore, we are not 
able to provide information on the accuracy of prostate cancer detection in this study or 
on the effect that potentially missed lesions might have had on our results. Furthermore, 
using histopathology slices for identification of tumor foci may have introduced a 
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potential bias in the evaluation of lesion volume on ADC maps as the location of tumors 
was available to the radiologists encircling the tumor foci. Although, the ROI drawn by 
the radiologists for the purposes of this study only contained clearly discernible tumor 
tissue on ADC maps (e.g. voxels that were visually darker than the surrounding healthy 
tissue), we acknowledge that the correlations reported in this study would be influenced 
by the diagnostic accuracy of prostate cancer detection in routine clinical practice.  
In summary, our results suggest that while VolumeADC  is useful to predict true 
tumor volume, ADCmean is the more useful parameter for distinguishing between GS 6 
and higher-Gleason-score tumors – a distinction that is critical for identifying suitable 
candidates for active surveillance.
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Tables 
Table 1 – Correlation between Tumor Volume on Histopathology and Tumor 
Volume on ADC Maps 
 
 ρ p-value Lesions Patients 
All tumors 0.683 <.0001 116 85 
PZ Tumors 0.706 <.0001 89 73 
TZ Tumors 0.677 0.0003 27 24 
GS 6 Tumors 0.453 0.1042 16 14 
GS 7 Tumors 0.643 <.0001 92 71 
GS ≥8 Tumors 0.980 <.0001 8 8 
Note: ρ = Spearman's correlation coefficient; PZ=peripheral zone; TZ=transition zone; GS = 
Gleason score. 95%CI was estimated using the bootstrapping method of resampling patients. 
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Table 2 – Results of Univariate and Multivariate Analyses for Prediction of Tumor 
Gleason score ≥7 by Mean Tumor ADC (ADCmean) and Tumor Volume Derived 
from ADC Maps (VolumeADC) 
 
 All lesions >0.5 mL PZ lesions >0.5 mL 
 OR (95%CI) p-Value OR (95%CI) 
p-
Value 
  Univariate Analysis 
ADCmean (100-unit increment) 0.64 (0.47, 0.86) 0.0033 0.50 (0.32, 0.78) 0.0025 
VolumeADC (0.5 mL increment) 1.73 (1.05, 2.87) 0.0325 1.50 (0.73, 3.07) 0.2709 
  Multivariate Analysis 
ADCmean (100-unit increment) 0.68 (0.50, 0.93) 0.0156 0.51 (0.33, 0.79) 0.0025 
VolumeADC (0.5 mL increment) 1.57 (0.96, 2.59) 0.0733 1.14 (0.66, 1.98) 0.6359 
Note: PZ= peripheral zone.  
Odds ratio (OR) interpretation: the tumors are less likely to have a Gleason score of 
7 or above as the ADCmean increases (OR for 100-unit increase = 0.68, 95%CI:  0.50-
0.93), controlling for VolumeADC. 
Transition zone tumors were not assessed separately due to the small number of 
lesions in the transition zone. 
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Figure Captions 
Figure 1 – Correlation of tumor volume derived from histopathology and tumor volume 
derived from ADC maps. 
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Figure 2 – Top row: Whole-mount histopathology slice (A) and ADC map (b=0, 1000 s/ 
mm2) (B) demonstrating a PCa focus with a Gleason score of 3+3 (arrows), a total 
tumor volume of 0.65 mL and a mean ADC of 1165.2 *10-6 mm2/s. The bottom row 
shows the whole-mount histopathology slice (C) and ADC map (b=0, 1000 s/mm2) (D) 
of a PCa focus with a Gleason score of 3+4 (arrows). Despite having a pathologic 
volume (0.68 mL) similar to that of the tumor focus in A, the tumor focus shown in C and 
D has a lower mean ADC (964.2 *10 6 mm2/s). Note: Images A and C show only one 
representative slice out of 12 and 8 total histopathology slices, respectively. The tumors 
in (A) and (C) were both present on 7 contiguous slices. 
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Figure 3 – Top row: Whole-mount histopathology slice (A) and ADC map (b=0, 1000 s/ 
mm2) (B) demonstrating a PCa focus with a Gleason score of 3+4 (arrows), a mean 
ADC of 1121.0 *10-6 mm2/s, and a total tumor volume of 0.65 mL. The bottom row 
shows a whole-mount histopathology slice (C) and ADC map (b=0, 1000 s/mm2) (D) of 
another PCa focus with a Gleason score of 3+4 (arrows) and a histopathologic volume 
of 2.03 mL. The mean ADC value of the tumor focus in C and D (1131.7 *10 6 mm2/s) is 
similar to that of the tumor focus in A and B, even though the volumes of the two foci 
differ substantially. Note: Images A and B show only one representative slice out of 8 
and 9 total histopathology slices, respectively. The tumors in (A) and (B) were present 
on 5 and 7 contiguous slices, respectively.
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Supplemental Material  
Figure Caption Supplemental Figure 1 - Results of receiver operating characteristic 
(ROC) analysis for the identification of tumors with a Gleason score ≥ 7.  A model 
combining mean tumor ADC value (ADCmean) and tumor volume derived from ADC maps 
(VolumeADC) performed only slightly better than ADCmean alone. (Note: AUC = area under 
ROC curve.) 
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 Supplemental Table 1 - Patient Demographics 
 Patients (n=131) 
Age at MRI (years); median 
(range) 60 (42-81) 
PSA at diagnosis [ng/mL]; 
median (range) 4.6 (0.5-33.9) 
Time between MRI and 
prostatectomy (days); median 
(range) 
22 (1-168) 
Clinical Stage at 
Prostatectomy*; n (%)  
T2a 20 (15) 
T2b 68 (52) 
T3a 33 (25) 
T3b 8 (6) 
T4 2 (2) 
GS at prostatectomy; n (%)  
3+3 26 (20) 
3+4 75 (57) 
4+3 22 (17) 
4+4 2 (1) 
4+5 5 (4) 
5+4 1 (1) 
*Staging according to AJCC 1997 (29). Note: GS = Gleason score. 
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Supplemental Table 2 - Lesion Characteristics  
 
Total Lesions; n 399 
Volume on histopathology [mL]; median (range) 0.14 (0.003-14.35) 
Total lesions > 0.5 mL; n (%) 116 (29.1) 
PZ; n (%) 89 (76.7) 
TZ; n (%) 27 (23.3) 
Volume [mL]; median (range) 0.96 (0.51-14.35) 
GS of lesions > 0.5 mL; n (%)  
3+3 16 (13.8) 
3+4 73 (62.9) 
4+3 19 (16.4) 
4+4 2 (1.7) 
4+5 5 (4.3) 
5+5 1 (0.9) 
 
Note: PZ = peripheral zone; TZ = transition zone; GS = Gleason score 
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